Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

PaperCitations, authors & open-access status

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3) is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 286 citations, 2016 year and hybrid oa status.